Toenail onychomycosis

An important global disease burden

J. Thomas, G. A. Jacobson, C. K. Narkowicz, G. M. Peterson, H. Burnet, C. Sharpe

Research output: Contribution to journalReview article

153 Citations (Scopus)

Abstract

Onychomycosis is a fungal infection of the nail plate or nail bed. It does not usually cure itself and it can trigger more infectious lesions in other parts of the body. The reported prevalence of onychomycosis is increasing in Western countries, presumably due to lifestyle changes and the ageing of the population. Approximately 10% of the general population, 20% of the population aged >60 years, up to 50% of people aged >70 years and up to one-third of diabetic individuals have onychomycosis. Care should be taken for the accurate diagnosis and timely treatment of toenail onychomycosis to prevent complications. Current treatment options have relatively limited therapeutic success, particularly long-term. Oral medications are associated with high recurrence rates and treatment failure, and are not suitable for many cases due to potential adverse effects. Topical medications are recommended only for mild to moderate cases. The cost of therapies may also be prohibitive in some cases. In the light of these issues, more research is warranted for the investigation and development of more effective and economical options for the treatment and prophylaxis of toenail onychomycosis. In patient populations such as diabetic individuals, where onychomycosis can provoke lower extremity complications, professional podiatry care of toenails and feet should be encouraged.

Original languageEnglish
Pages (from-to)497-519
Number of pages23
JournalJournal of Clinical Pharmacy and Therapeutics
Volume35
Issue number5
DOIs
Publication statusPublished - Oct 2010
Externally publishedYes

Fingerprint

Onychomycosis
Nails
Population
Podiatry
Therapeutics
Mycoses
Treatment Failure
Human Body
Global Burden of Disease
Life Style
Foot
Lower Extremity
Costs and Cost Analysis
Recurrence
Research

Cite this

Thomas, J., Jacobson, G. A., Narkowicz, C. K., Peterson, G. M., Burnet, H., & Sharpe, C. (2010). Toenail onychomycosis: An important global disease burden. Journal of Clinical Pharmacy and Therapeutics, 35(5), 497-519. https://doi.org/10.1111/j.1365-2710.2009.01107.x
Thomas, J. ; Jacobson, G. A. ; Narkowicz, C. K. ; Peterson, G. M. ; Burnet, H. ; Sharpe, C. / Toenail onychomycosis : An important global disease burden. In: Journal of Clinical Pharmacy and Therapeutics. 2010 ; Vol. 35, No. 5. pp. 497-519.
@article{0b7b3067fa8c4663b813f59f6d46f7d2,
title = "Toenail onychomycosis: An important global disease burden",
abstract = "Onychomycosis is a fungal infection of the nail plate or nail bed. It does not usually cure itself and it can trigger more infectious lesions in other parts of the body. The reported prevalence of onychomycosis is increasing in Western countries, presumably due to lifestyle changes and the ageing of the population. Approximately 10{\%} of the general population, 20{\%} of the population aged >60 years, up to 50{\%} of people aged >70 years and up to one-third of diabetic individuals have onychomycosis. Care should be taken for the accurate diagnosis and timely treatment of toenail onychomycosis to prevent complications. Current treatment options have relatively limited therapeutic success, particularly long-term. Oral medications are associated with high recurrence rates and treatment failure, and are not suitable for many cases due to potential adverse effects. Topical medications are recommended only for mild to moderate cases. The cost of therapies may also be prohibitive in some cases. In the light of these issues, more research is warranted for the investigation and development of more effective and economical options for the treatment and prophylaxis of toenail onychomycosis. In patient populations such as diabetic individuals, where onychomycosis can provoke lower extremity complications, professional podiatry care of toenails and feet should be encouraged.",
keywords = "dermatophytes, diagnosis, epidemiology, onychomycosis, toenail, treatment",
author = "J. Thomas and Jacobson, {G. A.} and Narkowicz, {C. K.} and Peterson, {G. M.} and H. Burnet and C. Sharpe",
year = "2010",
month = "10",
doi = "10.1111/j.1365-2710.2009.01107.x",
language = "English",
volume = "35",
pages = "497--519",
journal = "Journal of Clinical and Hospital Pharmacy",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "5",

}

Thomas, J, Jacobson, GA, Narkowicz, CK, Peterson, GM, Burnet, H & Sharpe, C 2010, 'Toenail onychomycosis: An important global disease burden', Journal of Clinical Pharmacy and Therapeutics, vol. 35, no. 5, pp. 497-519. https://doi.org/10.1111/j.1365-2710.2009.01107.x

Toenail onychomycosis : An important global disease burden. / Thomas, J.; Jacobson, G. A.; Narkowicz, C. K.; Peterson, G. M.; Burnet, H.; Sharpe, C.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 35, No. 5, 10.2010, p. 497-519.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Toenail onychomycosis

T2 - An important global disease burden

AU - Thomas, J.

AU - Jacobson, G. A.

AU - Narkowicz, C. K.

AU - Peterson, G. M.

AU - Burnet, H.

AU - Sharpe, C.

PY - 2010/10

Y1 - 2010/10

N2 - Onychomycosis is a fungal infection of the nail plate or nail bed. It does not usually cure itself and it can trigger more infectious lesions in other parts of the body. The reported prevalence of onychomycosis is increasing in Western countries, presumably due to lifestyle changes and the ageing of the population. Approximately 10% of the general population, 20% of the population aged >60 years, up to 50% of people aged >70 years and up to one-third of diabetic individuals have onychomycosis. Care should be taken for the accurate diagnosis and timely treatment of toenail onychomycosis to prevent complications. Current treatment options have relatively limited therapeutic success, particularly long-term. Oral medications are associated with high recurrence rates and treatment failure, and are not suitable for many cases due to potential adverse effects. Topical medications are recommended only for mild to moderate cases. The cost of therapies may also be prohibitive in some cases. In the light of these issues, more research is warranted for the investigation and development of more effective and economical options for the treatment and prophylaxis of toenail onychomycosis. In patient populations such as diabetic individuals, where onychomycosis can provoke lower extremity complications, professional podiatry care of toenails and feet should be encouraged.

AB - Onychomycosis is a fungal infection of the nail plate or nail bed. It does not usually cure itself and it can trigger more infectious lesions in other parts of the body. The reported prevalence of onychomycosis is increasing in Western countries, presumably due to lifestyle changes and the ageing of the population. Approximately 10% of the general population, 20% of the population aged >60 years, up to 50% of people aged >70 years and up to one-third of diabetic individuals have onychomycosis. Care should be taken for the accurate diagnosis and timely treatment of toenail onychomycosis to prevent complications. Current treatment options have relatively limited therapeutic success, particularly long-term. Oral medications are associated with high recurrence rates and treatment failure, and are not suitable for many cases due to potential adverse effects. Topical medications are recommended only for mild to moderate cases. The cost of therapies may also be prohibitive in some cases. In the light of these issues, more research is warranted for the investigation and development of more effective and economical options for the treatment and prophylaxis of toenail onychomycosis. In patient populations such as diabetic individuals, where onychomycosis can provoke lower extremity complications, professional podiatry care of toenails and feet should be encouraged.

KW - dermatophytes

KW - diagnosis

KW - epidemiology

KW - onychomycosis

KW - toenail

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=77956621286&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2710.2009.01107.x

DO - 10.1111/j.1365-2710.2009.01107.x

M3 - Review article

VL - 35

SP - 497

EP - 519

JO - Journal of Clinical and Hospital Pharmacy

JF - Journal of Clinical and Hospital Pharmacy

SN - 0269-4727

IS - 5

ER -